EMPEGFILGRASTIM: APPLICATION IN ONCOHEMATOLOGY


如何引用文章

全文:

详细

Extimia (empegfilgrastim) is the first original Russian drug from the group of granulocyte colony-stimulating factors for the prevention and treatment of febrile neutropenia, a dangerous infectious complication associated with the hematological toxicity of cancer chemotherapy. Being a pegylated form of filgrastim, empegfilgrastim has a more pronounced therapeutic effect, and also has an increased half-life. Over the past few years, the drug has confidently entered the clinical practice of Russian oncologists, however, there are no publications on the experience of its use in the field of oncohematology. This article presents the results of a retrospective comparison of two groups of patients who received chemotherapy for blood system tumors. Patients from the first group received empegfilgrastim as prevention and treatment of neutropenia, patients from the second group received filgrastim. The results showed that, on average, the use of empegfilgrastim th reduced the recovery period of the absolute number of neutrophils by 3 days, and the period of 4 grade neutropenia (agranulocytosis) by 3,8 days during intensive and high-dose chemotherapy courses. Also, the use of empegfilgrastim allowed patients with high and extremely high risks of developing febrile neutropenia to receive 10,3% more planned chemotherapy courses on time without reducing the dose rate of chemotherapy.

作者简介

D. Zhogolev

S.M. Kirov Military Medical Academy of the Ministry of Defense

St. Petersburg, Russia

I. Elykomov

Barnaul Regional Clinical Hospital Hematology department

Barnaul, Russia

A. Polyakov

S.M. Kirov Military Medical Academy of the Ministry of Defense

St. Petersburg, Russia

参考

  1. Переводчикова, Н.И. Руководство по химиотерапии опухолевых заболеваний / Н.И. Переводчикова [и др.]. - М.: Практическая меди-цина, 2015. - 686 с.
  2. Птушкин, В.В. Профилактика нейтропении при химиотерапии миелостимуляторами пролонгированного действия / В.В. Птушкин [и др.] // Онкогематология. - 2015. - №2. - С.37-45.
  3. Семелёв, В.Н. Особенности сопутствующей патологии и коморбидности у больных острыми миелоидными лейкозами моложе 60 лет / В.Н. Семелёв [и др.] // Вестн. Росс. Воен.-мед. акад. - 2019. - №1. - С.66-74.
  4. Сакаева, Д.Д. Практические рекомендации по лечению инфекционных осложнений фебрильной нейтропении и назначению коло-ниестимулирующих факторов у онкологических больных / Д.Д. Сакаева [и др.] // Злокачественные опухоли: Практические реко-мендации RUSSCO. - 2017. - №7. - С.486-495.
  5. Aapro, M.S. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemothera-py-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors / M.S. Aapro [et al.] // European journal of cancer. - 2011. - №1. - P.8-32.
  6. Crawford, J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer / J. Crawford [et al.] // The New England Journal of Medicine. - 1991. - №325. - P.167-170.
  7. Klastersky, J. Management of Febrile Neutropenia: ESMO Clinical Practice Guidelines / J. Klastersky [et al.] // Annals of Oncology. - 2016. - №5. - P.111-118.
  8. Lyman, G.H. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review / G.H. Lyman [et al.] // Critical Reviews in Oncology/Hematology. - 2014. - №3. - P.190-199.
  9. Mayordomo, J.I. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain / J.I. Mayordomo [et al.] // Current medical research and opinion. - 2009. - №10. - P.2533-2542.
  10. Moghnieh, R. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacte-remia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis / R. Moghnieh [et al.] // Frontiers in cellular and infection microbiology. - 2015. - №5. - P.11.
  11. Paesmans, M. Risk Assessment in Adult Cancer Patients with Febrile Neutropenia: A Review of Methods and of Risk-adapted Empiric Treat-ments / M. Paesmans [et al.] // Hospital Chronicles. - 2007. - №2. - P.66-73.
  12. Smith, T.J. 2015 Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update / T.J. Smith [et al.] // Journal of Clinical Oncology. - 2015. - №28. - P.3199-3212.
  13. Taplitz, R. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and Infectious Diseases of America Clinical Practice Guideline Update / R. Taplitz [et al.] // Journal of Clinical Oncology. - 2018. - №14. - P.1443-1453.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Zhogolev D.K., Elykomov I.V., Polyakov A.S., 2020

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).